Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)

v3.20.1
Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Jun. 30, 2019
Total assets $ 104,872 $ 65,147
Contingent consideration 7,850 12,600
Derivative instruments - cash flow hedges 18,725 12,458
Total liabilities 26,575 25,058
Fair Value, Inputs, Level 1 [Member]    
Total assets 99,287 65,147
Contingent consideration 0 0
Derivative instruments - cash flow hedges 0 0
Total liabilities 0 0
Fair Value, Inputs, Level 2 [Member]    
Total assets 5,585 0
Contingent consideration 0 0
Derivative instruments - cash flow hedges 18,725 12,458
Total liabilities 18,725 12,458
Fair Value, Inputs, Level 3 [Member]    
Total assets 0 0
Contingent consideration 7,850 12,600
Derivative instruments - cash flow hedges 0 0
Total liabilities 7,850 12,600
Equity Securities [Member]    
Investments, Fair Value Disclosure [1] 70,172 38,219
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]    
Investments, Fair Value Disclosure [1] 64,587 38,219
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]    
Investments, Fair Value Disclosure [1] 5,585 0
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]    
Investments, Fair Value Disclosure [1] 0 0
Certificates of Deposit [Member]    
Investments, Fair Value Disclosure [2] 34,700 26,928
Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]    
Investments, Fair Value Disclosure [2] 34,700 26,928
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]    
Investments, Fair Value Disclosure [2] 0 0
Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]    
Investments, Fair Value Disclosure [2] $ 0 $ 0
[1] Included in available-for-sale investments on the condensed consolidated balance sheet. The cost basis in the Company's investment in ChemoCentryx Inc (CCXI) was $7.6 million and $18.8 million as of March 31, 2020 and June 30, 2019, respectively. The Company has a warrant to purchase additional CCXI equity shares which was valued at $5.6 million as of March 31, 2020. The fair value of the warrant as of June 30, 2019 was not material.
[2] Included in available-for-sale investments on the condensed consolidated balance sheet. The certificates of deposit have contractual maturity dates within one year.